116 related articles for article (PubMed ID: 37846845)
1. Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.
Yan W; Xu J; Fan H; Li L; Cui J; Du C; Deng S; Sui W; Xu Y; Hao M; Anderson KC; Zou D; Qiu L; An G
Cancer; 2024 Feb; 130(3):421-432. PubMed ID: 37846845
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the Prognostic Value and Risk Factors of Early Relapse for Newly Diagnosed Multiple Myeloma Patients in the Era of Novel Agents].
Li QH; Liu Y; Wang J; Wang JJ; Dong F; Yang P; Wan W; Ke XY; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):148-153. PubMed ID: 36765492
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Mao X; Yan W; Mery D; Liu J; Fan H; Xu J; Xu Y; Sui W; Deng S; Zou D; Du C; Yi S; van Rhee F; Barlogie B; Shaughnessy JD; Anderson KC; Zhan F; Qiu L; An G
Am J Hematol; 2024 Apr; 99(4):523-533. PubMed ID: 38247315
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study.
Slade M; Fiala M; Kelley S; Crees ZD; Schroeder MA; Stockerl-Goldstein K; Vij R
Leuk Res; 2023 Apr; 127():107037. PubMed ID: 36801522
[TBL] [Abstract][Full Text] [Related]
5. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
6. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
[TBL] [Abstract][Full Text] [Related]
7. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
Fan H; Wang W; Zhang Y; Wang J; Cheng T; Qiu L; Wang X; Xia Z; An G
Cancer Biol Med; 2023 Jan; 20(1):77-87. PubMed ID: 36647781
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients.
Zaccaria GM; Bertamini L; Petrucci MT; Offidani M; Corradini P; Capra A; Romano A; Liberati AM; Mannina D; de Fabritiis P; Cascavilla N; Ruggeri M; Mina R; Patriarca F; Benevolo G; Belotti A; Gaidano G; Nagler A; Hájek R; Spencer A; Sonneveld P; Musto P; Boccadoro M; Gay F
Clin Cancer Res; 2021 Jul; 27(13):3695-3703. PubMed ID: 33926915
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).
Shi L; Yan W; Xu J; Li L; Cui J; Liu Y; Du C; Yu T; Zhang S; Sui W; Deng S; Xu Y; Zou D; Wang H; Qiu L; An G
Ann Hematol; 2024 Apr; 103(4):1305-1315. PubMed ID: 38049586
[TBL] [Abstract][Full Text] [Related]
10. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
[TBL] [Abstract][Full Text] [Related]
11. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
12. Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma.
Cheng Q; Zhao F; Zhang B; Zhang Y; Cai L; Qiao B; Hu Y; Sun C
Int Immunopharmacol; 2021 Oct; 99():108016. PubMed ID: 34385029
[TBL] [Abstract][Full Text] [Related]
13. [The Prognostic Value of Early Relapse after Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma].
Tian WW; Ren RR; Zheng FL; Zhu QJ; Gong R; Wang T; Gao ZL; Ma LM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):535-539. PubMed ID: 33812427
[TBL] [Abstract][Full Text] [Related]
14. High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.
Gu Y; Yuan YH; Xu J; Shi QL; Qu XY; Guo R; Bai H; Xu JD; Li JY; Chen LJ
Oncotarget; 2017 Jul; 8(29):48350-48361. PubMed ID: 28418851
[TBL] [Abstract][Full Text] [Related]
15. The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma.
Fan H; Yan W; Li L; Xu J; Liu J; Xu Y; Sui W; Deng S; Du C; Yi S; Zou D; Qiu L; An G
Hematology; 2023 Dec; 28(1):2182156. PubMed ID: 36815749
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis.
Manier S; Dimopoulos M; Hulin C; Leleu X; Delforge M; Weisel K; Mouro J; Costa B; Sturniolo M; Facon T
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e297-e306.e1. PubMed ID: 37393121
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma.
Zhang L; Chen S; Huang M; Wang W; Liang Y; Wang Y
Ann Hematol; 2023 Jan; 102(1):125-132. PubMed ID: 36441260
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: A real-world analysis.
Chen H; Shi H; Zhou N; Yu W; Wu L; Peng R; Wei W; Wang D; Zhou F
Eur J Haematol; 2023 Mar; 110(3):229-235. PubMed ID: 36366975
[TBL] [Abstract][Full Text] [Related]
19. Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.
Zhou H; Jian Y; Du J; Liu J; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Chen W; Fu W; Li J; Gao W
Cancer Med; 2023 Apr; 12(8):9085-9096. PubMed ID: 37021846
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of the clinical effects and outcome of patients with double-hit high-risk multiple myeloma].
Liu S; Shang J; Lin Y; Wang ZH; Wei TN; Lin L; Yang T; Chen WM
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1209-1214. PubMed ID: 34794226
[No Abstract] [Full Text] [Related]
[Next] [New Search]
